
Adaptive Biotechnologies (ADPT) Stock Forecast & Price Target
Adaptive Biotechnologies (ADPT) Analyst Ratings
Bulls say
Adaptive Biotechnologies is well-positioned for long-term success and its constant focus on innovation and expansion in the immune-driven medicine sector makes it a promising investment.
Bears say
Adaptive Biotechnologies is a company that has been growing at a consistent and accelerating rate in its MRD business, generating significant revenue and reaching profitability, with a diverse platform operating in both the diagnostic and pharma data services fields. However, concerns such as the termination of a collaboration agreement with Genentech and potential competition in the future may contribute to potential risks for the company. With a strong cash position and plans to expand its MRD business, the company may still have potential for growth but investors should closely monitor potential risks and industry developments in the coming years.
This aggregate rating is based on analysts' research of Adaptive Biotechnologies and is not a guaranteed prediction by Public.com or investment advice.
Adaptive Biotechnologies (ADPT) Analyst Forecast & Price Prediction
Start investing in Adaptive Biotechnologies (ADPT)
Order type
Buy in
Order amount
Est. shares
0 shares